Protagonist Therapeutics (PTGX) Receivables - Net (2017 - 2026)
Protagonist Therapeutics (PTGX) posted Receivables - Net of $53.7 million for Q1 2026, up 44249.59% sequentially from $121000.0 in Q4 2025.
Protagonist Therapeutics (PTGX) Receivables - Net (2017 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Receivables - Net for 10 years, with the latest figure at $53.7 million in Q1 2026.
- Quarterly Receivables - Net changed N/A year-over-year to $53.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.7 million (changed N/A YoY) and the FY2025 annual result came in at $121000.0, down 99.93% from the prior year.
- Receivables - Net grew to $53.7 million in Q1 2026 per PTGX's latest filing, from $121000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $165.0 million in Q4 2024 and troughed at $10000.0 in Q4 2022.
- A 5-year average of $24.5 million and a median of $123000.0 in 2022 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2025: Receivables - Net jumped 529.38% in 2022, then slumped 99.93% in 2025.
- Over 5 years, Receivables - Net stood at $10000.0 in 2022, then jumped by 290.0% to $39000.0 in 2023, then soared by 422976.92% to $165.0 million in 2024, then plunged by 99.93% to $121000.0 in 2025, then jumped by 44249.59% to $53.7 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $53.7 million, $121000.0, and $583000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.42 Mn |
| Jun 30, 2026 | 13.42 Mn |
| Mar 31, 2026 | 53.66 Mn |
| Mar 31, 2026 | 53.66 Mn |
| Dec 31, 2025 | 121,000.00 |
| Dec 31, 2025 | 121,000.00 |
| Sep 30, 2025 | 583,000.00 |
| Sep 30, 2025 | 583,000.00 |
| Dec 31, 2024 | 165.00 Mn |
| Dec 31, 2024 | 165.00 Mn |
| Jun 30, 2023 | 39,000.00 |
| Jun 30, 2023 | 39,000.00 |
| Mar 31, 2023 | 51,000.00 |
| Mar 31, 2023 | 51,000.00 |
| Dec 31, 2022 | 10,000.00 |
| Dec 31, 2022 | 10,000.00 |
| Sep 30, 2022 | 125,000.00 |
| Sep 30, 2022 | 125,000.00 |
| Jun 30, 2022 | 43,000.00 |
| Jun 30, 2022 | 43,000.00 |